VANCOUVER, BRITISH COLUMBIA--(Marketwired - May 17, 2013) - Verisante Technology, Inc. (TSX VENTURE:VRS)(OTCQX:VRSEF) (the "Company" or "Verisante"), announced today that it has closed its brokered private placement of 2,357,500 units ("Units") at a price of $0.40 per Unit for gross proceeds of $943,000 led by sole agent Raymond James Ltd. (the "Agent"). Each Unit consists of one common share of the Company and one common share purchase warrant (a "Warrant"). Each Warrant entitles the holder to acquire a common share at a price of $0.60 for a period of 24 months from the date of issuance.
The Warrants shall have two call provisions whereby in the event the volume weighted average trading price of Verisante's common shares on the TSX Venture Exchange (the "Exchange") is equal to or greater than $0.90 for 10 consecutive trading days, the Company will have the right to accelerate the expiry date of 50% of the total Warrants issued under the private placement to a date that is 30 days after Verisante issues a news release announcing that it has elected to exercise this acceleration right. Under the second call provision, in the event the volume weighted average trading price of Verisante's common shares on the Exchange is equal to or greater than $1.15 for 10 consecutive trading days, the Company will have the right to accelerate the expiry date of remaining 50% of the total Warrants issued under the private placement to a date that is 30 days after Verisante issues a news release announcing that it has elected to exercise this acceleration right.
The private placement is subject to all necessary regulatory and stock exchange approvals. Securities issued pursuant to the private placement are subject to a hold period of four months plus one day from the date of distribution.
The net proceeds of the private placement will be used to fund the Company's manufacturing of Aura™, to pursue additional regulatory approvals of Aura™ in the United States and other regions, to support sales and marketing initiatives, and for working capital requirements.
The Agent was paid a total of $60,400 as cash commission and was issued 151,000 agent's warrants in connection with this private placement.
About Verisante Technology, Inc.
Verisante is a medical device company committed to commercializing innovative systems for the early detection of cancer. The Verisante Aura™ for skin cancer detection and the Verisante Core™ series for lung, colon and cervical cancer detection utilize a proprietary cancer detection platform while the operating software and probe technology are unique to each device. The cancer detection platform was developed by the BC Cancer Agency and tested and refined at the Skin Care Centre at Vancouver General Hospital. This exclusive platform technology allows Verisante to develop and offer a range of compact, non-invasive cancer detection devices that offer physicians immediate results for many of the most common cancers. Aura™ has been approved for sale in Canada, Europe and Australia. The Core™ has not yet been approved for sale.
Verisante Aura™ was awarded Popular Science Magazine's "Best of What's New Award" for 2011, awarded a 2013 Prism Award for Innovation in Photonics and an Edison Award for Excellence in Innovation in 2013. Verisante Core™ was named one of the top 10 cancer breakthroughs of 2011 by the Canadian Cancer Society.
Forward Looking Statements
This release contains forward-looking statements, including, but not limited to, statements regarding the future commercialization of medical devices, the market demand for these products and the proprietary protections the Company will obtain with regard to the technology, all of which statements are subject to market risks, and the possibility that the Company will not be able to obtain patent protection or obtain sufficient customer demand. These statements are made based upon current expectations and actual results may differ from those projected due to a number of risks and uncertainties.
The TSX Venture Exchange has neither approved nor disapproved of the contents of this press release. Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.
